SCHEMBL1870030

SCHEMBL1870030

[S]N1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL702806 0.84
SCHEMBL2253031 0.80
SCHEMBL908136 0.80
Fluoride SCHEMBL7557871 0.76 CA1 (0.33)
SCHEMBL1258053 0.76
SCHEMBL1843941 0.73
SCHEMBL1871136 0.73
Hydrogen Peroxide SCHEMBL638036 0.54
Hydrogen Peroxide SCHEMBL638035 0.54
SCHEMBL14938 0.46

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4371979-A1 FORMAMIDE DERIVATIVE AND AGRICULTURAL OR HORTICULTURAL PLANT DISEASE CONTROL AGENT Kumiai Chemical Industry Co., Ltd. (JP) 2024-05-22 EP disclosed
US-20230089247-A1 NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA ZYDUS LIFESCIENCES LIMITED (IN) 2023-03-23 US disclosed
WO-2023286855-A1 FORMAMIDE DERIVATIVE AND AGRICULTURAL OR HORTICULTURAL PLANT DISEASE CONTROL AGENT クミアイ化学工業株式会社 2023-01-19 WO disclosed
CN-114901640-A Novel compounds useful for the treatment of dyslipidemia 兹杜斯生命科学有限公司 2022-08-12 CN disclosed
WO-2022130352-A1 NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA CADILA HEALTHCARE LIMITED (IN) 2022-06-23 WO disclosed
WO-2021130723-A1 NOVEL COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA CADILA HEALTHCARE LIMITED (IN) 2021-07-01 WO disclosed
EP-3083587-B1 OXIMINO DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA CADILA HEALTHCARE LTD (IN) 2018-04-04 EP disclosed
EP-3083587-A1 OXIMINO DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA Cadila Healthcare Limited (IN) 2016-10-26 EP disclosed
US-20160083380-A1 OXIMINO DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA CADILA HEALTHCARE LIMITED (IN) 2016-03-24 US disclosed
WO-2015107541-A1 OXIMINO DERIVATIVES FOR THE TREATMENT OF DYSLIPIDEMIA CADILA HEALTHCARE LIMITED (IN) 2015-07-23 WO disclosed
EP-2658851-A1 HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA Cadila Healthcare Limited (IN) 2013-11-06 EP disclosed
US-20130281366-A1 HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA CADILA HEALTHCARE LIMITED (IN) 2013-10-24 US disclosed
EP-2567957-A1 Compounds for the treatment of dyslipidemia and related diseases CADILA HEALTHCARE LIMITED (IN) 2013-03-13 EP disclosed
US-20120252796-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES CADILA HEALTHCARE LIMITED (IN) 2012-10-04 US disclosed
EP-2483266-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES Cadila Healthcare Limited (IN) 2012-08-08 EP disclosed
CN-102596941-A Compounds for the treatment of dyslipidemia and related diseases CADILA HEALTHCARE LTD 2012-07-18 CN disclosed
WO-2012090220-A1 HETEROCYCLIC COMPOUNDS SUITABLE FOR THE TREATMENT OF DYSLIPIDEMIA CADILA HEALTHCARE LIMITED (IN) 2012-07-05 WO disclosed
WO-2011051961-A1 COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES CADILA HEALTHCARE LIMITED (IN) 2011-05-05 WO disclosed
US-7217723-B2 Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. EISAI CO., LTD. (JP) 2007-05-15 US disclosed
US-20050227959-A1 Heterocyclic compound having oxime group EISAI CO., LTD. (JP) 2005-10-13 US disclosed